NCT03182634
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled central nervous system (CNS) disease- see trial for details
https://ClinicalTrials.gov/show/NCT03182634